HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Tolcapone

HCID 4659569
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
134308-13-7
Standard SMILES
Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1
InChIKey
MIQPIUSUKVNLNT-UHFFFAOYSA-N
Molecular formula
C14H11NO5
Average molar mass
273.24 g/mol
Monoisotopic mass
273.06372245

Overview

Tolcapone is benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase. It has a role as an EC 2.1.1.6 (catechol O-methyltransferase) inhibitor and an antiparkinson drug. It is a member of benzophenones, a member of catechols and a member of 2-nitrophenols.

Names & identifiers

Preferred name
Tolcapone
IUPAC
(3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone
English name
Tolcapone
Molecular formula
C14H11NO5
Molecular weight
273.24

Names & synonyms

Tolcapone134308-13-7Tasmar3,4-Dihydroxy-4'-methyl-5-nitrobenzophenoneRo 40-7592(3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanoneRo-40-7592(3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanoneDTXSID3023685Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)-TolcaponaCIF6334OLY
Show more names
ro40-7592TALCAPONETOLOCAPONED7-TolcaponeTOLCAPONE USPTolcaponeTolcaponeTolcapone (200 mg)Tolcapone USP/EP/BP
5-(4-methylbenzoyl)-3-nitrobenzene-1,2-diolRo-407592DTXCID9036853,4-dihydroxy-5-nitro-4'-methylbenzophenone4'-methyl-3,4-dihydroxy-5-nitrobenzophenoneCHEBI:63630N04BX015-[(4-METHYLPHENYL)CARBONYL]-3-NITROBENZENE-1,2-DIOL

Database identifiers

CAS
134308-13-7
PubChem CID
4659569
DTXSID
DTXSID3023685

Properties

Computed structural propertiesFilling in

XLogP
3.3
Topological polar surface area
103 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
5
Rotatable bonds
2
Heavy atoms
20
Formal charge
0
Complexity
372

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP · 2 items

4

2.9

Solubility5.69e-02 g/L
Human Drugs · 4 items

Breastfeeding; Lactation; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors;

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Physical DescriptionSolid
Collision Cross Section162.8 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID3023685]

Physicochemical properties

Melting point
126 · 126-1280C
Boiling point
485.6 · 485.6±45.0 °C(Predicted)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]

P273, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 2 notifications to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesAquatic Acute 1 (100%)

Toxicology

TreatmentHospitalization is advised. General supportive care is indicated. (L1712) Tolcapone-induced dyskinesia can be counteracted by decreasing the dose of L-DOPA (Wikipedia).
Health Effects · 1 item

Tolcapone has demonstrated significant hepatotoxicity that limits the drug's utility. Other side effects that result from the administration of Tolcapone regard the increase in dopaminergic activity, digestive symptoms and liver function. Treatment with tolcapone runs the risk of eliciting or prolonging dyskinesia. (Wikipedia)

Hepatotoxicity · 1 item

Tolcapone has been reported to cause serum aminotransferase elevations above 3 times the upper limit of normal in 1% to 5% of patients. While these abnormalities are usually asymptomatic and self-limiting, some persist if therapy is continued and resolved only with stopping tolcapone. More importantly, tolcapone has been implicated in several cases of severe, clinically apparent acute liver injury and at least three cases of death from acute liver failure. The onset of injury was insidious, arising 1 to 5 months after starting treatment. The pattern of serum enzyme elevations was hepatocellular and the clinical phenotype was similar to acute viral hepatitis. Immunoallergic manifestations were not present, but some patients had autoantibodies of unclear significance. Because of these reports, regular monitoring of serum aminotransferase levels has been mandated (every 2 to 4 weeks for the first 6 months of treatment and as clinically indicated thereafter) during tolcapone therapy, and treatment should be promptly discontinued if ALT or AST levels rise above twice the upper limit of the normal range or if signs or symptoms of liver injury are present.

Chemistry & industry

Pharmacology

ATC Code · 3 items

N04BX01

N - Nervous system

QN - Nervous system

Protein Binding> 99.9% (to serum albumin)
Pharmacodynamics · 1 item

Tolcapone is a potent, selective, and reversible inhibitor of catechol-O-methyltransferase (COMT). In humans, COMT is distributed throughout various organs. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa catalyzing it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery. When tolcapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that these sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease in patients as well as increased levodopa adverse effects, sometimes requiring a decrease in the dose of levodopa.

Mechanism of Action · 1 item

The precise mechanism of action of tolcapone is unknown, but it is believed to be related to its ability to inhibit COMT and alter the plasma pharmacokinetics of levodopa, resulting in an increase in plasma levodopa concentrations. The inhibition of COMT also causes a reduction in circulating 3-OMD as a result of decreased peripheral metabolism of levodopa. This may lead to an increase distribution of levodopa into the CNS through the reduction of its competitive substrate, 3-OMD, for transport mechanisms. Sustained levodopa concentrations presumably result in more consistent dopaminergic stimulation, resulting in greater reduction in the manifestations of parkinsonian syndrome.

Related reactions

1 records
New reaction record
HRID 1231867 reaction equation
HRID 1231867As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEMBL
CHEMBL1324
ChEBI
CHEBI:63630
UNII
CIF6334OLY
EC Number
694-343-9
Nikkaji
J459.846F
Density
1.419 · 1.419±0.06 g/cm3(Predicted)
storage temp.
2 · 2-8°C
solubility
15 mg/mL · DMSO: ≥15mg/mL
pka
4.78 · 4.78±0.38(Predicted)
form
powder
color
yellow
Stability
1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months.
Major Application
pharmaceutical (small molecule)
InChI
InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
InChIKey
MIQPIUSUKVNLNT-UHFFFAOYSA-N
SMILES
C(C1=CC([N+]([O-])=O)=C(O)C(O)=C1)(C1=CC=C(C)C=C1)=O
CAS DataBase Reference
134308 · 134308-13-7(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
6334 OLY · CIF6334OLY
NCI Drug Dictionary
Tasmar
ATC code
4 BX01 · N04BX01
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Protein binding
99.9 % · >99.9%
Excreted unchanged in urine
0.5 % · 0.5%
Volume of distribution
9 Litres · 9 Litres
Biological half-life
2 · 2-3 / Unchanged
Symbol(GHS)
9 · GHS09
Signal word
Warning
Hazard statements
400 · H400
Precautionary statements
273 · P273
Hazard Codes
N
Risk Statements
50 · 50
Safety Statements
61 · 61
RIDADR
3077 · UN 3077 9 / PGIII
RTECS
4952500 · PC4952500
HS Code
2914710000 · 2914710000
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
1 · Aquatic Acute 1
Toxicity
50 · mouse,LD50,oral,1600mg/kg (1600mg/kg),BEHAVIORAL: ATAXIABEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION,Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 24(Suppl,
Adverse Effects · 1 item

The most common dopaminergic adverse effects while taking tolcapone include nausea, postural hypotension, and dyskinesia. However, one study found a reduction of these adverse effects with a decrease in levodopa dosage. Other common adverse effects include diarrhea, urine discoloration, and drowsiness. Patients may also experience other central nervous system adverse effects such as insomnia, hallucinations, dizziness, headaches, depression, and fatigue.

Exposure RoutesOral, rapidly absorbed (absolute bioavailability is about 65%)
Toxicity Summary · 2 items

There is currently no antidote or treatment for overdose of tolcapone. If a patient experiences liver toxicity while on tolcapone, therapy should be discontinued. The mechanism of liver toxicity appears to occur in the metabolism pathway of tolcapone. A toxic intermediate may form, causing damage to the liver.

Tolcapone hepatoxicity can be attributed to elevated levels of transminases, but studies have shown that minimal risk exists for those without preexisting liver conditions when their enzyme levels were being monitored. No clear mechanism is implicated in tolcapone induced liver toxicity, but it has been hypothesized that it has something to do with abnormal mitochondrial respiration due to the uncoupling of oxidative phosphorylation. Dyskinesia occurs because the administration of Tolcapone results in the accumulation of the biological methyl donor S-adenosyl-L-methionine (SAM) in the striatum that works to induce symptoms of Parkinson's disease. (Wikipedia)

Signs and SymptomsDigestive symptoms include nausea, diarrhea, orthostatic hypotension, urine discoloration and dizziness. Tolcapone causes more severe diarrhea than entacapone. (Wikipedia)
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Tolcapone

vMost-DILI-concern

8

Box warning

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 1600 mg/kg (Oral, Rats) (A308)

Safety data

rtecs
PC4952500
ridadr
UN 3077 9 / PGIII
hs_code
2914710000
Toxicity
mouse,LD50,oral,1600mg/kg (1600mg/kg),BEHAVIORAL: ATAXIABEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION,Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 24(Suppl,
risk_code
50
Signal word
Warning
Symbol(GHS)
GHS09
hazard_code
N
safety_code
61
Storage Class
11 - Combustible Solids
Hazard statements
H400
Hazard Classifications
Aquatic Acute 1
Precautionary statements
P273
Biological Half-Life2-3.5 hours
Metabolism/Metabolites · 3 items

The main metabolic pathway of tolcapone is glucuronidation

Tolcapone has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[2-hydroxy-4-(4-methylbenzoyl)-6-nitrophenoxy]oxane-2-carboxylic acid.

The main metabolic pathway of tolcapone is glucuronidation. Route of Elimination: Tolcapone is almost completely metabolized prior to excretion, with only a very small amount (0.5% of dose) found unchanged in urine. The glucuronide conjugate of tolcapone is mainly excreted in the urine but is also excreted in the bile. Half Life: 2-3.5 hours

FDA Pharmacological Classification · 6 items

CIF6334OLY

TOLCAPONE

Mechanisms of Action [MoA] - Catechol O-Methyltransferase Inhibitors

Established Pharmacologic Class [EPC] - Catechol-O-Methyltransferase Inhibitor

Tolcapone is a Catechol-O-Methyltransferase Inhibitor. The mechanism of action of tolcapone is as a Catechol O-Methyltransferase Inhibitor.

TOLCAPONE

MeSH Pharmacological Classification · 2 items

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Compounds and drugs that inhibit or block the activity of CATECHOL O-METHYLTRANSFERASE enzymes. Drugs in this class are used in management of central nervous system disorders such as PARKINSON DISEASE.

Absorption, Distribution and Excretion · 4 items

Rapidly absorbed (absolute bioavailability is about 65%)

Tolcapone is almost completely metabolized prior to excretion, with only a very small amount (0.5% of dose) found unchanged in urine. The glucuronide conjugate of tolcapone is mainly excreted in the urine but is also excreted in the bile.

9 L

7 L/h

Cellular LocationsExtracellular

Uses & manufacturing

Uses · 2 items

Use (kg; approx.) in Germany (2009): >100

Used as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies.

Applications · 4 items

DescriptionTolcapone (134308-13-7) is a catechol O-methyltransferase inhibitor (COMT), inhibiting both brain and peripheral enzymes.1Potent inhibitor of alpha-synuclein and beta-amyloid oligomerization and fibrillogenesis protecting against extracellular toxicity.2Binds to transthyretin (TTR) with high affinity (21 to 58 nM) and inhibits TTR aggregation in human plasma and prevents TTR-induced cytotoxicityin vitro. Stabilizes TTR in mice and humansin vivo.3Inhibits O-methylation of exogenous polyphenols such as EGCG.4Cell permeable. Orally bioavailable.

UsesOrally active inhibitor of central and peripheral catechol-O-methyltransferase (COMT). Antiparkinsonian

UsesTolcapone may be used in COMT-mediated cell signaling studies.Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.

General DescriptionTolcapone, 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone (Tasmar), is a yellow, odorless, nonhygroscopic,crystalline compound (pKa=4.78). Tolcapone israpidly absorbed after oral administration. Tolcapone ishighly bound to plasma albumin (>98%), and its distributionis therefore restricted. Tolcapone has low first-pass metabolism.It is almost completely metabolized in the liver before excretion, and 60% is excreted by the kidney. The majormetabolite of tolcapone is an inactive glucuronide conjugate.COMT inhibitors increase chronotropic and arrhythmogeniceffects of epinephrine.Tolcapone is indicated as an adjunctto levodopa/carbidopa for the management of signs andsymptoms of PD.

Preparation methods

Preparationpreparation by demethylation of 4-hydroxy-3-methoxy-4′-methyl-5-nitrobenzophenone with hydrobromic acid in refluxing aque-ous acetic acid.

Upstream & downstream products

Upstream raw materials

Lithium ion (1+)Nitric acidHydrogen bromide4-Bromotoluene4-Benzyloxy-3-methoxybenzaldehyde
Additional notes · 1 item

DefinitionChEBI: Tolcapone is benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase. It has a role as an EC 2.1.1.6 (catechol O-methyltransferase) inhibitor and an antiparkinson drug. It is a member of benzophenones, a member of 2-nitrophenols and a member of catechols.